Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 490-491

  Jones, Jeffrey A ^a   Kraut, Eric H ^a   Deam, Deidre ^b   Byrd, John C ^a   Grever, Michael R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; DEXAMETHASONE; FLAVOPIRIDOL; HEMOGLOBIN; INTERFERON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOSTATIN; POTASSIUM; RASBURICASE; RITUXIMAB;

ADULT; BONE MARROW; CHRONIC KIDNEY FAILURE; CYTOPENIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HAIRY CELL LEUKEMIA; HUMAN; HYPERKALEMIA; LETTER; MALE; MULTIPLE CYCLE TREATMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SPLENECTOMY; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; HYPERKALEMIA; INTERFERONS; LEUKEMIA, HAIRY CELL; MALE; PENTOSTATIN; PIPERIDINES; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; SPLENECTOMY;

EID: 84863421651     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.600484     Document Type: Letter

References (8)

1. E lse M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
2. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-813. (Pubitemid 36917768)
3. Thomas DA, O' Brien S, Bueso-Ramos C., et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-3911. (Pubitemid 37486969)
4. K reitman RJ, Stetler-Stevenson M, Margulies I., et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin. Oncol. 2009;27:2983-2990.
5. Lin TS, Ruppert AS, Johnson AJ., et al. Phase II study of fl avopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin. Oncol. 2009;27:6012-6018.
6. Arons E, Suntum T, Stetler-Stevenson M., et al. VH4-34- hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-4695.
7. F orconi F, Sozzi E, Cencini E., et al. Hairy cell leukemias with unmutated IGHV genes defi ne the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696-4702.
8. Byrd JC, Shinn C, Waselenko JK., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-3816. (Pubitemid 28525207)